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INTRODUCTION
Autoimmune thyroid diseases consist of a wide spectrum
of clinical presentations, with Graves’ disease, Graves’ ophthal-
mopathy, Hashimoto’ s thyroiditis, and atrophic thyroiditis
(primary myxedema) (1, 2). Autoimmune thyroid diseases
share common immunologic evidences; lymphocytic infiltra-
tion of the thyroid, circulating thyroid autoantibodies, T cell
immunity, HLA association and familial aggregation. Autoan-
tibodies against the thyroid-stimulating hormone (TSH) re-
ceptor (TSH receptor antibodies, TSHRAbs) are directly
involved in the pathogenesis of Graves’ disease and autoim-
mune hypothyroidism. The TSHRAbs compete with TSH
for TSH receptor (TSHR) binding and mimic or block the
TSH action, resulting in hyperthyroidism and goiter or hy-
pothyroidism and thyroid atrophy, respectively. The hetero-
geneous nature of TSHRAbs is well established. Antibodies
capable of interacting with multiple epitopes on the TSH
receptor molecule and showing variable TSH activities, both
agonistic and antagonistic, are generally present in a given
patient. This variation in epitope specificity is reflected by the
influence of TSHRAbs on the TSHR function, as demonstrat-
ed by the occurrence of transplacentally transmitted hyper-
thyroidism or hypothyroidism in the fetuses of mothers with
high levels of circulating stimulating or blocking TSHRAbs
(1-4).
In recent years, a number of investigators have advanced
our understanding of how TSH and TSHRAbs interact with
TSHR (2, 5), delineating clinical implications of TSHRAbs.
The purposes of this review are, first, to summarize recent
advances in TSH receptor and its autoantibodies, and second,
to describe their potential clinical implications. 
CHARACTERISTICS OF TSH RECEPTOR
Gene and protein structure
The TSHR is a glycoprotein expressed on the cell membrane
of thyrocytes and a member of the large superfamily of G-
protein-coupled seven transmembrane receptors. The TSHR
gene has been cloned and sequenced (6, 7) and has been located
on the long arm of chromosome 14q31 (8), spans more than
60 kb and contains 10 exons. Exons 1-9 encode for the extra-
cellular domain (ECD) of the receptor, and exon 10 codes for
the transmembrane and the cytoplasmic domain. Exons 2-8
code for the leucine-rich repeats (LRRs) (7). The open leading
frame consists of 2,295 nucleotides encoding a 764-amino acid
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Clinical Applications of TSH Receptor Antibodies in Thyroid Diseases
The cloning and sequencing of thyroid-stimulating hormone (TSH) receptor (TSHR),
combined with advances in molecular techniques, have facilitated the understand-
ing of the interaction of the TSHR antibodies (TSHRAbs) with the TSHR at the
molecular level and have allowed the delineation of their clinical role. TSHRAbs in
vivo are functionally heterogeneous; the stimulating TSHRAbs cause hyperthy-
roidism and diffuse goiter in patients with Graves’ disease, whereas, the blocking
TSHRAbs cause hypothyroidism in some patients with autoimmune hypothyroidism
and are the cause of transient neonatal hypothyroidism. Measuring TSHRAbs has
potential clinical implications in differential diagnosis of Graves’ disease, predicting
the outcome of Graves’ disease after antithyroid drug treatment, and predicting
the fetal/neonatal hyperthyroidism or neonatal hypothyroidism. The existence of
epitope heterogeneity in a patient, i.e., of stimulating TSHRAbs with epitopes other
than on the N-terminal region of the extracellular domain, is significantly associated
with favorable long-term clinical response to antithyroid drug treatment. Measuring
these subtypes for thyroid-stimulating antibody (TSAb) has potential clinical impli-
cations, for example, in predicting responsiveness to treatment in untreated patients
with Graves’ disease.
Key Words : Receptors, Thyrotropin; TSH Receptor antibody; Epitope heterogeneity; Graves’ Disease;
Hyperthyroidism; Hypothyroidism
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protein. In the ECD, TSHR has 35-45% of homology with
lutenizing hormone/chorionic gonadotropin receptor (LH/
CGR) and follicle stimulating hormone receptor (FSHR).
The TSHR differs from LH/CGR by the presence of two
unique insertions of 8 (residues 38-45) and 50 amino acids
(residues 317-366) in the ECD (2, 5) (Fig. 1).
The ECD of human TSHR contains six potential aspara-
gines-linked glycosylation sites and at least two sites are gly-
cosylated (Fig. 1). The primary translation product of 85 kDa
TSHR is glycosylated, resulting in a high-mannose form of
~100 kDa, with subsequent maturation to a 120 kDa form
with complex carbohydrates (2, 4). TSH binding is increased
on mature, glycosylated form of the receptor, and mutation
of glycosylation sites reduces TSH binding (9). 
There are 11 cysteine residues in the ECD of TSHR that
could form five pairs, with one residue remaining as the or-
phan. Disulfide bonding is vital for the correct folding of the
TSHR and the maintenance of its tertiary conformation. At
present, however, there are no direct data to indicate which
cysteines form the five pairs. 
Two subunits model of the TSH receptor
In vitro studies suggest that the TSHR is present not only
as a single chain, but also in a two-subunit form (10, 11). The
glycosylated ECD, the A subunit, is cleaved from the mem-
brane-spanning B subunit and these two subunits are linked
by disulfide bonds (2). The amino-terminal cleavage site is
located between residues 302 and 317 in proximity to a basic
domain formed by residues 310-313 (10, 12). The carboxy-
terminal cleavage site seems to be located between residues
367-369 (Fig. 1). Although there is some debate whether the
cleavage site is two or not, recent studies suggest that the ini-
tial cleavage at the amino-terminal site is followed by progres-
sive cleavage or degradation to the amino-terminal site or,
alternatively, rapid degradation of the putative connecting
peptide (10, 12). The physiologic significance of the cleavage
and shedding phenomenon remains unresolved.
Intracellular signaling through TSH receptor
TSH binding to its receptor leads to coupling Gs and
stimulates cAMP production through activation of adenylyl
cyclase (13). At higher concentrations of TSH, the TSHR
couples Gq/11, resulting in activation of phospholipase C,
and stimulates the inositol phosphate (IP) pathway (13). The
increase in cAMP leads to phosphorylation of protein kinase
A and to activation of transcription factors, such as CREB,
resulting in the increase of iodide uptake, thyroid peroxidase,
and thyroglobulin synthesis (13). In addition, stimulation of
Gq/11 and the phospholipase C-dependent inositol phosphate
/diacylglycerol pathway at the higher doses of TSH activates
hydrogen peroxide generation and iodination. Graves’ im-
munoglobulins (IgG) can enhance both cAMP and IP pro-
duction in FRTL-5 cells as well as in cells transfected with
human TSHR cDNA (14). The physiological significance
of this dual signaling system and the clinical role of the IP
pathway in Graves’ disease still remain to be defined. 
TSH and autoantibody binding to the TSH receptor
Several approaches have been used to map the sites on TSHR
responsible for TSH or TSHRAbs binding, all having serious
problems. These include the use of synthetic peptide sequences
and anti-peptide antibodies as well as site-directed mutagen-
esis. Although studies using synthetic peptides have provided
useful information on functionally important sites on TSHR,
they failed to provide conclusive evidence for TSHRAbs inter-
action with TSHR (2), for the following reasons; they could
identify only linear and non-glycosylated binding sites, but
TSH and TSHRAbs were expected to interact with nonlinear
conformational epitopes. 
Site-directed mutagenesis has been used to facilitate the
search for TSH-binding sites and for epitopes of TSHRAbs.
Several studies have shown that TSH and TSHRAbs interact
with TSHR at different sites. From chimeric TSHR-LH/CGR
data, important TSH contact points are present in the mid-
region (residues 171-260) and carboxyl-terminal segments
(residues 261-418) of the TSHR ectodomain (15). Homolo-
gous or nonhomologous substitutions in the TSHR suggest
that amino acids between 201-211, 222-230, 295-302, and
387-395 are the binding sites for TSH (15, 16). Thus, the
binding sites of TSH on the ECD of TSHR are multiple, non-
linear, and discontinuous.
In several reports using chimeric TSHR-LH/CGR, most
patients with Graves’ disease were found to have one or more
stimulating TSHAbs epitope(s) on the N-terminal portion
of the ECD of TSHR, whereas the major blocking TSHRAb
epitope in patients with hypothyroidism and idiopathic myx-
edema was located in the C-terminus (17-19). The N-ter-
minal third of the TSHR (amino acids 8-165) is necessary for
TSHRAb stimulation. The epitope for blocking TSHRAb
on the ECD of TSHR overlaps with, but is not precisely the
Fig. 1. Schematic representation of TSH receptor structure.



























c csame as, the TSH-binding site and the stimulating TSHRAb
epitope. Overlap between these three ligands is greatest in the
C-terminal region of the ECD of TSHR (Fig. 2). 
TSHRAb ASSAYS
TSHRAbs can be detected by two techniques. 1) TSHRAbs
compete with TSH for receptor binding, and are detected by
radioreceptor assay based on the competitive inhibition of
125I-TSH binding on TSHR. The TSHRAb detected by this
assay is designated TSH binding inhibitor immunoglobulin
(TBII). 2) TSHRAbs stimulate the adenylyl cyclase system
that leads to the production of cAMP, or blocks TSH-stim-
ulated cAMP production in an in vitro thyroid cell bioassay.
The TSHRAb detected by this bioassay is designated thy-
roid-stimulating antibody (TSAb, stimulating TSHRAb)
or thyroid stimulation blocking antibody (TSBAb, blocking
TSHRAb), respectively. Each of these assays has different
diagnostic effectiveness, limitations, and clinical utility. The
classification of TSHAbs based on their effect on thyroid
cell function and their detection methods are listed in Table 1.
TBII assay
In the TBII assay system, TSHR preparation and 
125I-labeled
TSH are essential components. Porcine thyroid receptor pro-
tein has been established as an adequate alternative to human
TSH receptors because of its ready availability and stability
(20). Purified bovine TSH has higher biological activity than
human TSH and is a more suitable 
125I-labeled ligand for this
assay. This test’ s simplicity, precision, and cost-effectiveness,
along with its commercial availability, have made it the most
widely used test in clinical laboratories. However, there are a
number of limitations to this assay. The TBII assay does not
differentiate between the TSH-binding inhibitory antibodies
that stimulate (TSAbs) and those that block the TSH activ-
ity (TSBAbs). In addition, about 10% or more of clinically
hyperthyroid Graves’ patients test negative with the TBII
assay (21), a finding that may be caused by the use of TSHR
and TSH from heterologous species (porcine TSHR and bo-
vine TSH) that may influence the detection of autoantibod-
ies to the human TSHR (22).
A recently developed second-generation assay for TBII uses
recombinant human TSHR expressed in eukaryotic cells,
grown in suspension at a high density (23). The hTSHR was
then captured in the test tubes coated with a monoclonal anti-
body to native TSHR. This assay showed better diagnostic
sensitivity (99%) and specificity (99%) than the convention-
al TBII assay. 
Bioassays for TSHRAbs measurement
Thyroid-stimulating antibody assay
After a sensitive cAMP response to TSH or TSHRAbs in
cultured human thyrocytes using a medium free of sodium
chloride for incubation was demonstrated (24), direct mea-
surement of cAMP in the medium (instead of within the cells)
simplified this assay and significantly enhanced its sensitivi-
ty. Later the assay was further simplified and made practical
by using rat thyroid cell line called FRTL-5 instead of human
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Fig. 2. Schematic structure of the wild type TSH receptor and
two TSH and LH/CG receptor chimeras designated as Mc1+2
and Mc2, illustrating binding sites for TSH, TBII, TSBAb and
major and minor binding epitopes for TSAb subtypes. The
amino acid numbers indicate the restriction sites used for
chimeras. TSH, TSAb, and TBII responses in these cell lines are
depicted as graded positive or negative in the table (bottom).
The TSAb-2 epitope was considered to be minor because of its
low level of reactivity in Mc1+2 or Mc2 cell lines and is boxed in
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TBII    Inhibits 
125I-TSH Radioreceptor assay: inhibition of 125I-TSH
binding to TSHR  binding to soluble porcine TSHR or
recombinant human TSHR
TSAb Stimulates cAMP Bioassay: % increase in cAMP over 
production, iodine   normal serum in cultured thyrocytes 
uptake, Tg synthesis (FRTL-5, hTSHR expressed CHO cells)
TSBAb Inhibits TSH-induced Bioassay: % inhibition of 
cAMP production, TSH-induced cAMP production 
iodine uptake, compared to normal serum
Tg synthesis
TBII, TSH binding inhibitor immunoglobulin; TSAb, thyroid-stimulating
antibody; TSBAb, thyroid stimulation blocking antibody; Tg, thyroglob-
ulin.
Antibody     Function                                 Detection method
Table 1. Classification of TSHRAbs based on functional activ-
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thyroid cells. Nevertheless, the major limitation of FRTL-5
cells has been the meticulous culture conditions they require,
including expensive 6-hormone (including TSH) medium
and growth for 3-5 days in TSH-deprived medium (3). Fur-
thermore, in our experience (18), the FRTL-5 bioassay fails
to detect stimulating activity in roughly 10 to 20% of patients
with Graves’ disease. The reported diagnostic sensitivity gen-
erally ranges between 75 and 90%.
The stable expression of the human TSHR in CHO (CHO-
TSHR) cells has combined the advantage of detecting TSAb
activity with a homologous receptor and the ready availabil-
ity compared to FRTL-5 cells (2). The TSHR density is 5- to
10-times higher in CHO-TSHR cells than in FRTL-5 cells
or human thyroid cells. This enhances analytical sensitivity,
thus allowing detection of some borderline positive patients
(2, 3). Thus, the use of CHO-TSHR cells reduces the frequen-
cy of false negative results seen with the FRTL-5 cells (18).
The reported diagnostic sensitivity ranges between 90 and
95% (18). Further advantages are that CHO-TSHR cells are
easier to maintain in culture, they do not require lengthy
pre-culture time for assay, and they are superior to FRTL-5
cells in accuracy, simplicity, and cost (3). 
Thyroid stimulation blocking antibody assay
Some patients with atrophic hypothyroidism have antibod-
ies that block TSH binding and action (25). These blocking
antibodies (TSBAbs) compete with TSH for receptor binding
and block the biological effects of TSH on thyroid cells, includ-
ing cAMP production, iodine uptake, and thyroid cell growth
(26-28). They induce transient neonatal hypothyroidism when
transferred across the placenta (29, 30). TSBAb assay quan-
titates inhibition by autoantibodies of the increase in cAMP
production or the iodide uptake in response to a standard
concentration of TSH in the FRTL-5 cell (26-28) or CHO-
TSHR cell (31, 32). 
HETEROGENEITY OF TSHRAbs
The heterogeneous nature of TSHRAbs in terms of function
and epitopes is well recognized. A single patient has func-
tionally different kinds of TSHRAbs. In addition, since the
molecular cloning of the TSHR, it has become possible to
discern epitopic differences even within a population of autoan-
tibodies with similar function. 
Functional heterogeneity
It has been well known that there are two primary types
of functional TSHRAbs: 1) TSHRAbs that stimulate the
adenylyl cyclase-cAMP cascade through TSHR and cause
hyperthyroidism and goiter (TSAb); and 2) TSHRAbs that
block TSH binding and action, thereby causing atrophic
hypothyroidism (TSBAb). In addition, recently neutral
TSHRAbs, which neither stimulate the TSHR nor block
TSH action, have been also demonstrated (33).
It is well established that not all TSHRAbs that inhibit
TSH binding to the TSHR are stimulatory. In fact, there has
been no good correlation between TSAb and TBII activities
in Graves’ disease patients in many reports (1, 2). This dis-
crepancy between TBII and TSAb activities might be related
to species specificity, as porcine receptor has been used for
most TBII studies and rat thyroid cells for most TSAb stud-
ies. However, the correlation between these two activities
was also weak when using recombinant human TSHR for
TBII and human thyroid cells for TSAb (34). Thus, the cause
of the disparity is more likely to be the TSBAbs that are detect-
ed in the TBII assay but, in fact, mask TSAb activity in the
bioassay (32). 
The functional heterogeneity of TSHRAbs was confirmed
by Kohn et al. (35), who found that the clones generated from
lymphocytes from a hypothyroid woman included TSAb-
producing clones with weak TBII activity and a number of
TBII-positive clones with TSH-blocking activity. Further-
more, recently, we demonstrated that 18.5% of patients with
hyperthyroid Graves’ disease had both TSBAb and TSAb
activities (32). Thus, sera from most patients with Graves’
disease contain both TSAb and TSBAb/TBII activities, and
the clinical effect may depend on the relative concentration
and affinity of the predominating antibody.
Epitope heterogeneity 
Heterogeneity within the stimulating TSHRAbs with
respect to epitope recognition on TSHR has been demonstrat-
ed using chimeras of the human TSHR and the LH/CGR
(18, 19, 36). Using such a chimeric cell line, Kim et al. recently
reported that patients with Graves’ disease have been divid-
ed into two subgroups according to the TSHRAbs epitopes
distribution (18). Of 66 patients studied, 45 patients (68%)
had stimulating TSHRAbs with homogeneous epitope dis-
tribution that recognize only the N terminus (residues 90-
165) of the TSHR ectodomain. Heterogeneous epitope dis-
tribution, with epitopes other than on the N-terminus of the
TSHR, occurred in 21 patients (32%). Moreover, the func-
tional stimulating TSHRAb epitope changed from residues
90-165 to residues outside this region in half of the patients
with Graves’ disease during treatment of hyperthyrodism (19).
Patients with heterogeneous epitope for stimulating TSHRAb
initially or developed during treatment are more responsive
to antithyroid drug treatment (18, 19). Thus, this epitope
heterogeneity in patients with Graves’ disease has clinical
implications.
CLINICAL APPLICATIONS
Diagnostic values in Graves’ diseaseClinical Applications of TSH Receptor Antibodies in Thyroid Diseases 297
Graves’ disease is an organ-specific autoimmune disease
caused by stimulating TSHRAb that stimulate the thyroid
function and growth, resulting in hyperthyroidism and dif-
fuse goiter. Thus, theoretically, the detection of TSHRAb in
a hyperthyroid patient is diagnostic of Graves’ disease. How-
ever, because 80% or more of patients with Graves’ disease
have a diffuse goiter and homogeneous thyroid scan, it is likely
that most patients can be diagnosed by thyroid hormones
measurements without TSHRAb testing. Thus, TSHRAb
measurement has not been recommended as a routine inves-
tigation in recent guidelines (37, 38). However, assays for
TSHRAbs is helpful in diagnosing patients with mild hy-
perthyroidism and small or no goiter and may also be useful
in differentiating Graves’ disease from other forms of thyrotoxi-
cosis, such as toxic nodular goiter, painless (autoimmune)
thyroiditis, or factitious thyrotoxicosis. TSHRAbs measure-
ments may also be helpful for pregnant women or patients
with recent iodine load where radioiodine uptake or thyroid
scan is contraindicated. In a patient who presents with Graves’
ophthalmopathy but is biochemically euthyroid, TSHRAb
assay may be valuable in confirming the diagnosis of Graves’
disease. 
TSAb measurements tend to be more sensitive (85-100%)
than TBII measurements (75-96%) in untreated Graves’
patients (23, 39). The new more sensitive and precise assays
using CHO-TSHR are positive in as much as 98% of patients
with untreated Graves’ disease (23). Thus, TSAb by CHO-
TSHR is a better biologic marker than TBII and should be
preferred for diagnostic purposes.
Guiding choice of treatment modality in Graves’ disease
The major problem with antithyroid drug is the high relapse
rate (approximately 50% or more) after 1-2 yr of treatment.
Thus, it is clinically important to identify patients who are
likely to achieve remission with antithyroid drug treatment.
In general, however, most reported studies suggest that initial
TSHRAb activity has not had satisfactory positive and negative
predictive values for remission or relapse after antithyroid
drug treatment (40, 41). Nevertheless, taking into account
the initial titer of TSHRAb and other clinical parameters such
as, age, gender, goiter size, the severity of hyperthyroidism,
and the presence of ophthalmopathy, subgroups of patients
can be identified as harboring a high or low risk of relapse.
In a study by Vitti et al. (42), the combination of a small
goiter (<40 mL) and low TBII level (<30 U/L) conferred a
45% chance of remission during the 5 yr after completion
of 12-24 months course of antithyroid drug treatment. In
contrast, patients with a large goiter (>70 mL) and a higher
TBII level had less than a 10% chance to remain in remis-
sion. 
As discussed above, it has been reported that patients with
heterogeneous epitope for stimulating TSHRAb initially or
developed during treatment are more responsive to antithyroid
drug treatment (18, 19). Approximately 30% of patients
initially have heterogeneous epitope for stimulating TSHRAbs
whose activity depends on sites other than the N-terminal
locus. In patients with heterogeneous epitope, 94% became
euthyroid within 3 months, whereas this was true of only 70%
of patients with homogeneous epitope. Furthermore, there
was a decrease in the duration of antithyroid drug therapy
necessary to achieve a euthyroid state in the heterogeneous
epitope group. Thus, the authors (18) demonstrated for the
first time that patients with a heterogeneous population of
stimulating TSHRAbs involving receptor determinants other
than the N-terminus have a better clinical response to antithy-
roid therapy. Recently we expanded this observation in 159
patients with Graves’ disease for 4 to 7 yr (43). In 52 patients
(32.7% of 159) with heterogeneous epitope of stimulating
TSHRAb, 34 patients maintained remission for more than
12 months, with 65.4% of success rate of antithyroid drug
therapy. However, 46 out of 107 patients, whose IgGs had
activities of stimulating TSHRAb with homogeneous epitope,
attained remission after antithyroid drug therapy with 43.0%
of rate. Thus, the success rate of antithyroid drug therapy in
the heterogeneous epitope group, was significantly higher
than that in the homogeneous epitope group (p=0.011).
While the overall average rate of success is about 50%, the
combination of a heterogeneous TSAb epitope and low TBII
titer (≤40%) conferred a 82% chance of remission, and a
patient with a homogeneous TSAb epitope and high TBII
titer (>40%) has a 32% chance of remission. Likewise, com-
bination of heterogeneity of TSAb with size of goiter and
initial T3 concentration had different probability of success
ranging from 32 to 74% (Table 2).   
The existence of epitope heterogeneity in a patient, i.e., of
stimulating TSHRAbs with epitopes other than on the N-
terminal region of the extracellular domain, is, therefore, sig-
Smaller goiter+Heterogeneous epitope 20/28 (71.4%)
Larger goiter+Homogeneous epitope 19/60 (31.7%)
Low T3+Heterogeneous epitope 17/23 (73.9%)
High T3+Homogeneous epitope 15/46 (32.6%)
Low TBII+Heterogeneous epitope 22/27 (81.5%)
High TBII+Homogeneous epitope 15/47 (31.9%)
Smaller goiter, none/small on clinical examination; Larger goiter, medi-
um/large on clinical examination; Heterogeneous epitope, group who
had IgG with residual TSAb activity in the chimeras; Homogeneous
epitope, group with epitope only in the N-terminal portion of the extra-
cellular domain; Low T3, total T3 concentration was 350 ng/dL or less
than 350 ng/dL; High T3, total T3 concentration was more than 350 ng/dL;
Low TBII, titer of TBII was 40% or less than 40%; High TBII, titer of TBII
was more than 40%.
Combination of parameters  Success rate
Table 2. Success rate after antithyroid drug treatment accord-
ing to combination of heterogeneity of epitope for TSAb with
other prognostic parametersnificantly associated with favorable long-term clinical response
to antithyroid drug treatment. We suggest, therefore, that
the measurement of difference in epitopes for TSHRAbs in
patients with untreated Graves’ hyperthyroidism may be use-
ful to predict the long-term outcome after antithyroid drug
treatment.
Monitoring the response to therapy in Graves’ disease
In general, most studies demonstrate that the titers of
TSHRAb (TBII and/or TSAb) are decreased during treatment
and their falling titers indicate a good response (44). One
question merits consideration: could the determination of
TSHRAb during antithyroid drug treatment contribute to
the adaptation of the treatment plan to each case or be ben-
efit for the patient to monitor the level of TSHRAb during
treatment? Previously Cho et al. (41) reported that in a 174
patients with an overall remission rate of 52%, the proportion
of remitters was much higher among patients treated for 24
months who had become TBII-negative with normal basal
TSH after 6 (94% remission rate) or 12 (75% remission rate)
months of treatment than in patients whose TSHRAb had
remained detectable for 18 (63% remission rate) or 24 months
(52% remission rate). Thus, the rate of fall of TSHRAb dur-
ing antithyroid drug treatment is predictive of subsequent
outcome. 
The duration of antithyroid drug treatment can be adapted
to the TSHRAb status. Cho et al. (41) previously reported
that the remission rate of patients, whose treatment was dis-
continued on the normalization of their TSHRAbs and TSH
levels, was not significantly different from that of patients,
who were treated for 24 months irrespective of their TSH
levels and TSHRAbs activities (52% vs 63%, p<0.05). The
mean treatment of duration of the former group was 10
months, 14 months shorter than the latter group. These
findings suggest that the sequential monitoring of TSHRAb
during the treatment of Graves’ disease gives valuable infor-
mation concerning the optimum time for withdrawal of med-
ication. 
Because the TSHRAb stimulates the thyroid function and
results in hyperthyroidism in Graves’ disease, theoretically,
the disappearance of TSHRAbs at the end of the treatment
reflects remission. However, in a recent report of meta-anal-
ysis that included 18 studies comparing the relapse rate in
TSHRAbs-positive and -negative patients, only 10 of 18
studies showed a statistically significant difference (44). The
authors concluded that the absence of TSHRAb was signifi-
cantly protective against relapse, but that it was indicative of
either relapse or remission after antithyroid drug treatment in
individual patients. As recently discussed by Davies et al. (37),
variations in the effectiveness of the assays, along with the
known heterogeneity of TSHRAbs and the fact that block-
ing antibodies are detected differently by TBI or TSAb assays,
may have an impact on the final analysis. Furthermore, as
discussed above, our data suggest that both TSAb and TBAbs
are heterogeneous (18, 19, 31, 32) and that a subtype of TSAb
detected by chimeric TSHR is associated with increased re-
sponsiveness to antithyroid drug therapy (18, 43). 
Guidelines for the management of Graves’ disease in
pregnancy
Although maternal TSHRAbs values normally decline
during the third trimester, an elevated TSAb level at 28 to
30 weeks of gestation is associated with an increased frequency
of Graves’ hyperthyroidism in the neonate (45). The recom-
mendations of European Thyroid Association for measuring
TSHRAbs in pregnancy can be summarized as follows (46):
1. Euthyroid women without medication and previously
treated with antithyroid drugs alone: no TSHRAbs testing
is required.
2. Women previously treated with radioiodine or surgery
for Graves’ disease: measure TSHRAbs early in pregnancy.
If the level is high, the fetus should be monitored closely for
signs of hyperthyroidism and antithyroid drugs treatment
for mother should be considered. Antibody titers should be
repeated in the last trimester.
3. Women currently treated with antithyroid drugs: adjust-
ment of treatment is needed to achieve a high-normal level
of free T4 in the mother. TSHRAbs should be checked in the
last trimester.
TSHRAb and autoimmune hypothyroidism
Indeed, the pathogenetic role of blocking TSHRAb in
autoimmune hypothyroidism is suggested not only by their
prevalence but also by their capacity to induce neonatal
transient hypothyroidism. The reported prevalence of these
antibodies in atrophic autoimmune thyroiditis varies greatly,
raging from 14% (47) to 59% (28). In our study (28), the
prevalences of TBII in goitrous and atrophic thyroiditis were
6.3% and 48% and those of TSBAb were 10.5% and 59%,
respectively. 
It has been well documented that transient neonatal hy-
pothyroidism can be induced by transplacental transfer of
maternal TSBAb since the first report of Matsuura et al. in
1980 (29). TBII and TSBAb were detected in 5% and 4%,
respectively, among the mothers of hypothyroid newborns.
On the whole, antibody-related transient neonatal hypothy-
roidism accounts for 1% of all causes of congenital hypothy-
roidism. Thus, transient transplacental neonatal hypothy-
roidism is as predictable as feto-neonatal hyperthyroidism
by the assay of TBII and, if positive, by an assay of TSBAb
during the last trimester (39). Epidemiologic data suggest
that this screening is indicated in those with atrophic thy-
roiditis (primary myxedema). 
298 B.Y. ChoMonitoring fluctuating thyroid function 
Spontaneous evolution of hyperthyroid Graves’ disease to
hypothyroidism has been well characterized (48). Although
thyroid destruction caused by concomitant autoimmune
thyroiditis has been proposed as the major pathogenetic
mechanisms of this phenomenon, the presence of blocking
TSHRAbs is considered to be another possible cause (31,
49). TSBAbs may result from a conversion of the bioactivity
of TSAb or may coexist with TSAb at the time of hypothy-
roidism. In addition, several patients with fluctuating thy-
roid function from hypothyroidism to hyperthyroidism by
changing the activity of TSBAb to TSAb have been reported
(50). Thus, the measurement of bioactivities of TSHRAbs
during the course of Graves’ disease is valuable in the case,
especially, of fluctuating thyroid function. 
CONCLUSION
The cloning and sequencing of TSHR, combined with
advances in molecular techniques, have facilitated the under-
standing of the interaction of the TSHRAbs with the TSHR
at the molecular level and have allowed the delineation of
their clinical role. Recently developed new techniques con-
firm that TSHRAbs in vivo are functionally or epitopically
heterogeneous, and indicate that the thyroid function may
depend on the balance of the functional activities of TSHRAbs.
In addition, the existence of epitope heterogeneity in a patient
is significantly associated with apparently long-term clinical
response to antithyroid drug treatment. Measuring these
subtypes for TSAb has potential clinical implications, for
example, in predicting responsiveness to treatment in Graves’
disease. Table 3 summarizes the author’ s view on the current
clinical indications for the use of TSHRAbs measurements. 
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